Merck KGaA and Pfizer have joined BioXcel and Nektar Therapeutics' clinical collaboration to test Bavencio in combination with two other cancer therapies as a treatment for pancreatic cancer.
Original Article: Merck KGaA, Pfizer added to BioXcel’s pancreatic cancer deal